Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Manley

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Pharmacology|March 15, 2006
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell linesHans Prenen, Gunther Guetens, Gert de Boeck, et al.
Leukemia Research|June 27, 2006
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kitSrdan Verstovsek, Cem Akin, Taghi Manshouri, et al.
Genes & Cancer|July 23, 2011
Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity ComparisonEllen Weisberg, Johannes Roesel, Pascal Furet, et al.
Cancer Cell|September 6, 2008
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activationChristine Dierks, Ronak Beigi, Gui-Rong Guo, et al.
Cancer|August 4, 2005
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cellsSrdan Verstovsek, Mirna Golemovic, Hagop Kantarjian, et al.
Nature Chemical Biology|January 18, 2006
Allosteric inhibitors of Bcr-abl-dependent cell proliferationFrancisco J Adrián, Qiang Ding, Taebo Sim, et al.
Haematologica|December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibDeborah L White, Jerald Radich, Simona Soverini, et al.
The New England Journal of Medicine|June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLHagop Kantarjian, Francis Giles, Lydia Wunderle, et al.
Transplantation Direct|January 19, 2019
Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of TransmissionSarah L White, William Rawlinson, Peter Boan, et al.
Nephrology (Carlton, Vic.)|January 4, 2012
KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant RecipientsSteven J Chadban, Katherine A Barraclough, Scott B Campbell, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Pharmacology|March 15, 2006
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell linesHans Prenen, Gunther Guetens, Gert de Boeck, et al.
Leukemia Research|June 27, 2006
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kitSrdan Verstovsek, Cem Akin, Taghi Manshouri, et al.
Genes & Cancer|July 23, 2011
Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity ComparisonEllen Weisberg, Johannes Roesel, Pascal Furet, et al.
Cancer Cell|September 6, 2008
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activationChristine Dierks, Ronak Beigi, Gui-Rong Guo, et al.
Cancer|August 4, 2005
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cellsSrdan Verstovsek, Mirna Golemovic, Hagop Kantarjian, et al.
Nature Chemical Biology|January 18, 2006
Allosteric inhibitors of Bcr-abl-dependent cell proliferationFrancisco J Adrián, Qiang Ding, Taebo Sim, et al.
Haematologica|December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibDeborah L White, Jerald Radich, Simona Soverini, et al.
The New England Journal of Medicine|June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLHagop Kantarjian, Francis Giles, Lydia Wunderle, et al.
Transplantation Direct|January 19, 2019
Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of TransmissionSarah L White, William Rawlinson, Peter Boan, et al.
Nephrology (Carlton, Vic.)|January 4, 2012
KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant RecipientsSteven J Chadban, Katherine A Barraclough, Scott B Campbell, et al.
Pageof 4